Middle East Cystic Fibrosis Association MECFA

MECFA Blog

News & Articles

Lung structure abnormalities seen on CT predict success with Trikafta

New findings explain wide variability in therapy's effects among CF patients by Marisa Wexler, MS People with cystic fibrosis (CF) who have certain lung structure abnormalities — ones visible on CT scans — are more likely than those with other issues also seen via imaging to experience improvements in lung function after starting treatment with Trikafta . That’s according to the results of a new analysis that used imaging scans and artificial intelligence (AI) tools to asse

Kaftrio success leaves some CF patients feeling forgotten

Adults not eligible for approved therapy report conflicting emotions by Steve Bryson, PhD | Adults with cystic fibrosis (CF) who are not eligible for Kaftrio therapy reported feeling forgotten in both the media and research, with conflicting emotions about those who do benefit from the approved treatment, according to a new interview-based study by researchers in the U.K. Study participants noted that they also felt a loss of hope when they realized they weren’t eligible f

BiomX To Continue Cystic Fibrosis Study With Revised Dosing Of BX004; Data Expected In Q2, 2026

Written by RTTNews.com for RTTNews (RTTNews) - BiomX Inc. (PHGE), a clinical stage biopharmaceutical company, announced that an independent Data Monitoring Committee has completed a safety review of adverse events reported in its Phase 2b trial of BX004 in cystic fibrosis. The independent Data Monitoring Committee has recommended that the study continue with revised dosing. Accordingly, the study protocol will be updated, and topline results are now expected in Q2 2026. BX00

Generic form of antibiotic for CF lung infections wins FDA approval

Tobramycin inhalation solution offers affordable option to patients 6 and older by Marisa Wexler, MS The U.S. Food and Drug Administration (FDA) has approved a new generic form of inhaled tobramycin , an antibiotic that’s used to treat bacterial lung infections in people with cystic fibrosis (CF). The newly approved therapy, tobramycin inhalation solution, will be sold by The Ritedose Corporation through its generics division, Ritedose Pharmaceuticals. It is indicated to tr

Dual-action therapy for cystic fibrosis shows promise: Study

Experimental compound 3b addresses disease itself, viral threats by Michela Luciano, PhD | Researchers in Italy have developed a new experimental compound called 3b, which has shown early promise as a dual-action therapy for cystic fibrosis (CF). It addresses the dysfunction of the CFTR protein that causes the disease, as well as protects against viral threats that can worsen lung problems. In lab tests, compound 3b restored CFTR activity, blocked the growth of several resp